Oppenheimer has reiterated an Outperform Rating for Endologix Inc ELGX after attending management meetings.
According to Oppenheimer, "After spending time with ELGX management on the road this week, we remain convinced that ELGX has the best product pipeline in AAA and that the new products will help meaningfully expand ELGX market share over the next few years. Next year (2012) is the start of the breakout period for the pipeline with key launches in the US and EU. We believe the trialing of competitor products near term remains at this point within management's expectations and we maintain our '11 sales growth estimate of 20%."
ELGX has a $10.00 Price Target and closed yesterday at $6.66 a share.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in